Biomarkers and surrogate end points in clinical trials of tuberculosis treatment

J Infect Dis. 2007 Aug 15;196(4):648-9; author reply 649-50. doi: 10.1086/519744.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antitubercular Agents / therapeutic use*
  • Biomarkers
  • Clinical Trials as Topic
  • Humans
  • Recurrence
  • Treatment Outcome
  • Tuberculosis / drug therapy*
  • Tuberculosis / pathology

Substances

  • Antitubercular Agents
  • Biomarkers